St. Luke’s Provides Treatment for COVID ‘Long Haulers’

April 16, 2021

St. Luke’s has introduced its new COVID Recovery Clinic, a program dedicated to the treatment of post-COVID-19 patients with lingering symptoms.

St. Luke’s recognizes the prevalence of “long COVID” symptoms and the need to care for patients afflicted by these symptoms appropriately.  Incorporating the expertise of a half dozen different kinds of medical specialists, the program promises a coordinated, multidisciplinary approach to Post-Acute Sequelae of COVID, known as PASC.  Participants will benefit from specialized evaluation and a personalized treatment plan.

“Many people recovering from COVID continue to have long-lasting symptoms that impact their day-to-day lives. St. Luke’s is committed to helping these patients get access to the most appropriate care so they can find relief,” said St. Luke’s Senior Regional Medical Director Dennis McGorry, MD, who is spearheading the program.

Nationally, PASC of varying severity is being reported in up to 30% of adults and children following COVID infection.

Most typical COVID cases resolve in four weeks, explained Jeffrey Jahre, MD, St. Luke’s Vice President of Medical & Academic Affairs and Section Chief Emeritus of Infectious Diseases.  But for some, the symptoms aren’t going away. “Patients are going to their doctor, asking, ‘What’s wrong with me?’ In many cases, people are not getting the appropriate care.”

The most common after-effects these patients, or “long haulers,” experience include extreme fatigue, memory impairment, known as “brain fog,” anxiety and depression, breathing difficulty and heart muscle irregularities or irregular heartbeats.

Patients with persistent symptoms beyond four weeks are advised to go to their St. Luke’s primary care physician, who will be able to evaluate them and may refer them to the COVID Recovery Clinic for further treatment by appropriate medical specialists.

Depending on a patient’s specific symptoms and their severity, treatment can include cognitive and memory retraining, physical and occupational therapy, medication and group therapy for behavioral health issues as well as other interventions to address neurologic, pulmonary and cardiac problems.

St. Luke’s has taken steps to help providers manage PASC, such as building a “smart set” algorithm into the electronic medical record system. The smart set guides physicians on ordering tests and imaging scans based on patients’ symptoms.

While some COVID after-effects may be mild, McGorry said, “The key is not missing something serious like a pulmonary embolism or cardiomyopathy (heart muscle issue) in these patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”